Rena Ottavio, Papalia Esther, Oliaro Alberto, Ruffini Enrico, Filosso Pierluigi, Novero Domenico, Maggi Giuliano, Casadio Caterina
Thoracic Surgery Department, University of Eastern Piedmont 'A. Avogadro', Novara, Italy.
Eur J Cardiothorac Surg. 2007 Jan;31(1):109-13. doi: 10.1016/j.ejcts.2006.10.022. Epub 2006 Nov 15.
To determine whether or not patients with completely resected Masaoka stage II thymoma benefit from postoperative radiotherapy (RT).
We retrospectively review the case records and compared the long-term outcomes of patients affected by Masaoka stage II thymoma treated by resection alone with same stage thymoma patients submitted to resection and RT. Surgical specimens were reviewed to confirm pathological stage, negative resection margins and histological subtype.
Between 1988 and 2000, we performed 197 resections for thymoma; 58 patients resulted to be affected by completely resected tumours with microscopic transcapsular invasion (stage IIA, n=25) or macroscopic invasion into the surrounding fatty tissue with or without adhesion to the mediastinal pleura (stage IIB, n=33). Thirty-two patients underwent only complete surgical resection (14 stage IIA and 18 stage IIB); 26 patients underwent complete resection and subsequent mediastinal RT (11 stage IIA and 15 stage IIB). RT dosages were 45-54grays (Gy), in 25-30 fractions. Histological subtypes were similarly represented in both groups. Median follow-up was 91 months (range 9-170). Five intrathoracic recurrences occurred: three radiated patients (2 stage IIB - 1 AB and 1 B2 thymoma; 1 stage IIA B1 thymoma) and two not-radiated patients (1 stage IIA AB thymoma and 1 stage IIB B1 thymoma). Disease-free survival rate at 5- and 10-year were 94% and 87%, respectively. Log-rank test showed no difference in Kaplan-Meier survival curves (p=0.432) between radiated and not-radiated patients.
These data support the concept that radical surgical resection alone should be considered a sufficient treatment for stage II thymoma.
确定完全切除的Masaoka II期胸腺瘤患者是否能从术后放疗(RT)中获益。
我们回顾性分析病例记录,并比较了单纯手术切除的Masaoka II期胸腺瘤患者与接受手术切除及放疗的同阶段胸腺瘤患者的长期预后。对手术标本进行复查以确认病理分期、切缘阴性及组织学亚型。
1988年至2000年间,我们对197例胸腺瘤患者进行了手术切除;58例患者的肿瘤被完全切除,伴有镜下包膜侵犯(IIA期,n = 25)或肉眼侵犯周围脂肪组织,伴或不伴有纵隔胸膜粘连(IIB期,n = 33)。32例患者仅接受了完整的手术切除(14例IIA期和18例IIB期);26例患者接受了完整切除及随后的纵隔放疗(11例IIA期和15例IIB期)。放疗剂量为45 - 54格雷(Gy),分25 - 30次给予。两组的组织学亚型分布相似。中位随访时间为91个月(范围9 - 170个月)。发生了5例胸内复发:3例接受放疗的患者(2例IIB期 - 1例AB型和1例B2型胸腺瘤;1例IIA期B1型胸腺瘤)和2例未接受放疗的患者(1例IIA期AB型胸腺瘤和1例IIB期B1型胸腺瘤)。5年和10年无病生存率分别为94%和87%。对数秩检验显示,接受放疗和未接受放疗的患者的Kaplan - Meier生存曲线无差异(p = 故0.432)。
这些数据支持了这样一种观点,即对于II期胸腺瘤,单纯根治性手术切除应被视为一种充分的治疗方法。